Are the Protean Effects of Pentoxifylline in the Therapy of Diabetes and Its Complications Still Relevant?

In a placebo-controlled randomized prospective study performed primarily to study diabetic nephropathy Px decreased fasting glucose by 18 mg/dl ( p = 0.009) and HbA1c by 0.43% ( p = 0.002) with a barely significant decrease in HOMA-IR ( p = 0.04).

also in 875 other papers

All studies showed a trend toward improved cognitive function but in three of the studies, which utilized a stricter definition of vascular dementia, there were significant differences between placebo and the Px treatment groups [ 45 ].

also in 53,322 other papers